Duloxetine updated on 07-01-2025

Preeclampsia

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S11747
R43161		 Huybrechts (Controls unexposed, NOS), 2020 Pre-eclampsia (ICD-9 codes 642.4x, 642.5x, 642.6x, and 642.7x) early pregnancy retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes Monotherapy: no or not specified 1.12 [0.96;1.31] 171/3,059   48,599/1,447,644 48,770 3,059
ref
S11722
R43082		 Palmsten, 2013 Preeclampsia and/or eclampsia (ICD-9 codes 642.4x–642.7x, after 140 gestational days and within 30 days after the delivery) 2nd and/or 3rd trimester retrospective cohort (claims database) unexposed, sick Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) 0.89 [0.43;1.83] -/-   3,215/59,219 - -
ref
Total 2 studies 1.11 [0.95;1.29] 48,770 3,059
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Huybrechts (Controls unexposed, NOS), 2020Huybrechts, 2020 1 1.12[0.96; 1.31]48,7703,05996%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: low Palmsten, 2013Palmsten, 2013 0.89[0.43; 1.83]--4%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.11[0.95; 1.29]48,7703,0590.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.11[0.95; 1.29]48,7703,0590%NAHuybrechts (Controls unexposed, NOS), 2020 Palmsten, 2013 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.12[0.96; 1.31]48,7703,059 -NAHuybrechts (Controls unexposed, NOS), 2020 1 unexposed, sickunexposed, sick 0.89[0.43; 1.84]-- -NAPalmsten, 2013 1 Tags Adjustment   - Yes  - Yes 1.11[0.95; 1.29]48,7703,0590%NAHuybrechts (Controls unexposed, NOS), 2020 Palmsten, 2013 2 Monotherapy   - no or not specified  - no or not specified 1.12[0.96; 1.31]48,7703,059 -NAHuybrechts (Controls unexposed, NOS), 2020 1   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 0.89[0.43; 1.84]-- -NAPalmsten, 2013 1 Unexposed sick   - recent illness/treatment (during o ...  - recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) 0.89[0.43; 1.84]-- -NAPalmsten, 2013 1 All studiesAll studies 1.11[0.95; 1.29]48,7703,0590%NAHuybrechts (Controls unexposed, NOS), 2020 Palmsten, 2013 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.12[0.96; 1.31]48,7703,059 -NAHuybrechts (Controls unexposed, NOS), 2020 1 unexposed, sick controlsunexposed, sick controls 0.89[0.43; 1.84]3,206- -NAPalmsten, 2013 10.510.01.0